Global Systemic Psoriasis Therapeutics Market 2018-2022: Market to Grow by Over 10% - Key vendors are AbbVie, Amgen, Celgene & Johnson & Johnson

News provided by

Research and Markets

06:45 ET

DUBLIN, Aug 31, 2018 /PRNewswire/ --

The "Global Systemic Psoriasis Therapeutics Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

The Global Systemic Psoriasis Therapeutics Market to grow at a CAGR of 10.07% during the period 2018-2022.

This report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. To calculate the market size, the report considers the revenue generated from sale of different systemic psoriasis therapeutics.

One trend affecting this market is the rise in cost of systemic psoriasis therapy. The cost of the treatment depends on the severity of the disease. The first line of treatment is usually a systemic agent, and if ineffective a more potent systemic agent is used which increases the cost of treatment.

According to the report, one driver influencing this market is the need for affordable therapies. Topical treatments are most often purchased medication. Biologics are the most expensive medication and treatment failure can increase the medication cost.

Further, the report states that one challenge affecting this market is the patent expiry of drugs. The patent for major biologics for systemic psoriasis therapy have expired, which increases chances of adoption of biosimilars.

Key vendors

  • AbbVie
  • Amgen
  • Celgene
  • Johnson & Johnson

Key Topics Covered:



PART 01: EXECUTIVE SUMMARY



PART 02: SCOPE OF THE REPORT



PART 03: RESEARCH METHODOLOGY



PART 04: MARKET LANDSCAPE



PART 05: MARKET SIZING 2017-2022



PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: PIPELINE ANALYSIS

  • Pipeline analysis
  • Discontinued psoriasis therapies

PART 08: MARKET SEGMENTATION BY PRODUCT

  • Segmentation by product
  • Comparison by product
  • Small molecules
  • Biologics
  • Market opportunity by product

PART 09: MARKET SEGMENTATION BY ROA

  • Oral
  • Parenteral

PART 10: MARKET SEGMENTATION BY SEVERITY OF DISEASE



PART 11: MARKET SEGMENTATION BY END-USER

  • Segmentation by end-user
  • Hospitals
  • Retail pharmacies

PART 12: CUSTOMER LANDSCAPE



PART 13: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Market opportunity

PART 14: DECISION FRAMEWORK



PART 15: DRIVERS AND CHALLENGES



PART 16: MARKET TRENDS

  • Rise in cost of systemic psoriasis therapy
  • Introduction of biologics
  • Gene therapy for psoriasis
  • Use of combination therapy
  • Research in precision healthcare infrastructure

PART 17: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 18: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors

For more information about this report visit https://www.researchandmarkets.com/research/29vcqq/global_systemic?w=5

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com   



For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com